Cluster analysis of antiphospholipid antibodies-associated adverse pregnancy outcome patients: based on a 13-years cohort study
Antiphospholipid antibodies (aPLs) are the leading causes of adverse pregnancy outcomes (APOs). We conducted cluster analysis to identify distinct phenotypes among aPLs-associated APOs patients. This approach aims to facilitate risk stratification and improve pregnancy outcomes for obstetric APS. Th...
Saved in:
| Published in | Clinical and experimental medicine Vol. 23; no. 8; pp. 5377 - 5388 |
|---|---|
| Main Authors | , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Cham
Springer International Publishing
01.12.2023
Springer Nature B.V |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Antiphospholipid antibodies (aPLs) are the leading causes of adverse pregnancy outcomes (APOs). We conducted cluster analysis to identify distinct phenotypes among aPLs-associated APOs patients. This approach aims to facilitate risk stratification and improve pregnancy outcomes for obstetric APS. This was a retrospective study of persistent aPLs positive women cohort in Peking Union Medical College Hospital. Baseline demographic characteristics, clinical manifestation, previous APOs and antibodies profiles were included for hierarchical cluster analysis. Placentae from portions of patients were collected and performed the histopathologic diagnoses. Four clusters among 209 patients with 477 pregnancies were identified. Cluster 1 comprised patients with triple aPLs positivity and demonstrates a high incidence of gestational hypertension (34.92%,
P
< 0.05) and preterm delivery (20.63%,
P
< 0.05). Patients in cluster 2 were characterized by lupus anticoagulant (LA) positivity, with high risk of whole gestational APOs. Cluster 3 included patients with isolated aPLs-IgM isotype combined with early miscarriage (60.92%,
P
= 0.016). Patients in cluster 4 majorly presented aPLs-IgG isotype combined with placenta insufficiency (22.73%). During the follow-up, the live birth rate in cluster 1 and 2 was only 69.20%. Placenta pathology revealed the most severe impairment within cluster 1, whereas clusters 3 and 4 exhibited relatively milder damage. By cluster analysis, we identified four clinical subtypes of aPLs-associated APOs patients. Patients with triple antibodies or high-risk lupus characteristics were prone to occurred gestational hypertension and premature delivery. Isolated LA or aCL/aβ2GPI positivity were found to be more frequently associated with early-stage fetal loss. |
|---|---|
| AbstractList | Antiphospholipid antibodies (aPLs) are the leading causes of adverse pregnancy outcomes (APOs). We conducted cluster analysis to identify distinct phenotypes among aPLs-associated APOs patients. This approach aims to facilitate risk stratification and improve pregnancy outcomes for obstetric APS. This was a retrospective study of persistent aPLs positive women cohort in Peking Union Medical College Hospital. Baseline demographic characteristics, clinical manifestation, previous APOs and antibodies profiles were included for hierarchical cluster analysis. Placentae from portions of patients were collected and performed the histopathologic diagnoses. Four clusters among 209 patients with 477 pregnancies were identified. Cluster 1 comprised patients with triple aPLs positivity and demonstrates a high incidence of gestational hypertension (34.92%,
P
< 0.05) and preterm delivery (20.63%,
P
< 0.05). Patients in cluster 2 were characterized by lupus anticoagulant (LA) positivity, with high risk of whole gestational APOs. Cluster 3 included patients with isolated aPLs-IgM isotype combined with early miscarriage (60.92%,
P
= 0.016). Patients in cluster 4 majorly presented aPLs-IgG isotype combined with placenta insufficiency (22.73%). During the follow-up, the live birth rate in cluster 1 and 2 was only 69.20%. Placenta pathology revealed the most severe impairment within cluster 1, whereas clusters 3 and 4 exhibited relatively milder damage. By cluster analysis, we identified four clinical subtypes of aPLs-associated APOs patients. Patients with triple antibodies or high-risk lupus characteristics were prone to occurred gestational hypertension and premature delivery. Isolated LA or aCL/aβ2GPI positivity were found to be more frequently associated with early-stage fetal loss. Antiphospholipid antibodies (aPLs) are the leading causes of adverse pregnancy outcomes (APOs). We conducted cluster analysis to identify distinct phenotypes among aPLs-associated APOs patients. This approach aims to facilitate risk stratification and improve pregnancy outcomes for obstetric APS. This was a retrospective study of persistent aPLs positive women cohort in Peking Union Medical College Hospital. Baseline demographic characteristics, clinical manifestation, previous APOs and antibodies profiles were included for hierarchical cluster analysis. Placentae from portions of patients were collected and performed the histopathologic diagnoses. Four clusters among 209 patients with 477 pregnancies were identified. Cluster 1 comprised patients with triple aPLs positivity and demonstrates a high incidence of gestational hypertension (34.92%, P < 0.05) and preterm delivery (20.63%, P < 0.05). Patients in cluster 2 were characterized by lupus anticoagulant (LA) positivity, with high risk of whole gestational APOs. Cluster 3 included patients with isolated aPLs-IgM isotype combined with early miscarriage (60.92%, P = 0.016). Patients in cluster 4 majorly presented aPLs-IgG isotype combined with placenta insufficiency (22.73%). During the follow-up, the live birth rate in cluster 1 and 2 was only 69.20%. Placenta pathology revealed the most severe impairment within cluster 1, whereas clusters 3 and 4 exhibited relatively milder damage. By cluster analysis, we identified four clinical subtypes of aPLs-associated APOs patients. Patients with triple antibodies or high-risk lupus characteristics were prone to occurred gestational hypertension and premature delivery. Isolated LA or aCL/aβ2GPI positivity were found to be more frequently associated with early-stage fetal loss.Antiphospholipid antibodies (aPLs) are the leading causes of adverse pregnancy outcomes (APOs). We conducted cluster analysis to identify distinct phenotypes among aPLs-associated APOs patients. This approach aims to facilitate risk stratification and improve pregnancy outcomes for obstetric APS. This was a retrospective study of persistent aPLs positive women cohort in Peking Union Medical College Hospital. Baseline demographic characteristics, clinical manifestation, previous APOs and antibodies profiles were included for hierarchical cluster analysis. Placentae from portions of patients were collected and performed the histopathologic diagnoses. Four clusters among 209 patients with 477 pregnancies were identified. Cluster 1 comprised patients with triple aPLs positivity and demonstrates a high incidence of gestational hypertension (34.92%, P < 0.05) and preterm delivery (20.63%, P < 0.05). Patients in cluster 2 were characterized by lupus anticoagulant (LA) positivity, with high risk of whole gestational APOs. Cluster 3 included patients with isolated aPLs-IgM isotype combined with early miscarriage (60.92%, P = 0.016). Patients in cluster 4 majorly presented aPLs-IgG isotype combined with placenta insufficiency (22.73%). During the follow-up, the live birth rate in cluster 1 and 2 was only 69.20%. Placenta pathology revealed the most severe impairment within cluster 1, whereas clusters 3 and 4 exhibited relatively milder damage. By cluster analysis, we identified four clinical subtypes of aPLs-associated APOs patients. Patients with triple antibodies or high-risk lupus characteristics were prone to occurred gestational hypertension and premature delivery. Isolated LA or aCL/aβ2GPI positivity were found to be more frequently associated with early-stage fetal loss. Antiphospholipid antibodies (aPLs) are the leading causes of adverse pregnancy outcomes (APOs). We conducted cluster analysis to identify distinct phenotypes among aPLs-associated APOs patients. This approach aims to facilitate risk stratification and improve pregnancy outcomes for obstetric APS. This was a retrospective study of persistent aPLs positive women cohort in Peking Union Medical College Hospital. Baseline demographic characteristics, clinical manifestation, previous APOs and antibodies profiles were included for hierarchical cluster analysis. Placentae from portions of patients were collected and performed the histopathologic diagnoses. Four clusters among 209 patients with 477 pregnancies were identified. Cluster 1 comprised patients with triple aPLs positivity and demonstrates a high incidence of gestational hypertension (34.92%, P < 0.05) and preterm delivery (20.63%, P < 0.05). Patients in cluster 2 were characterized by lupus anticoagulant (LA) positivity, with high risk of whole gestational APOs. Cluster 3 included patients with isolated aPLs-IgM isotype combined with early miscarriage (60.92%, P = 0.016). Patients in cluster 4 majorly presented aPLs-IgG isotype combined with placenta insufficiency (22.73%). During the follow-up, the live birth rate in cluster 1 and 2 was only 69.20%. Placenta pathology revealed the most severe impairment within cluster 1, whereas clusters 3 and 4 exhibited relatively milder damage. By cluster analysis, we identified four clinical subtypes of aPLs-associated APOs patients. Patients with triple antibodies or high-risk lupus characteristics were prone to occurred gestational hypertension and premature delivery. Isolated LA or aCL/aβ2GPI positivity were found to be more frequently associated with early-stage fetal loss. Antiphospholipid antibodies (aPLs) are the leading causes of adverse pregnancy outcomes (APOs). We conducted cluster analysis to identify distinct phenotypes among aPLs-associated APOs patients. This approach aims to facilitate risk stratification and improve pregnancy outcomes for obstetric APS. This was a retrospective study of persistent aPLs positive women cohort in Peking Union Medical College Hospital. Baseline demographic characteristics, clinical manifestation, previous APOs and antibodies profiles were included for hierarchical cluster analysis. Placentae from portions of patients were collected and performed the histopathologic diagnoses. Four clusters among 209 patients with 477 pregnancies were identified. Cluster 1 comprised patients with triple aPLs positivity and demonstrates a high incidence of gestational hypertension (34.92%, P < 0.05) and preterm delivery (20.63%, P < 0.05). Patients in cluster 2 were characterized by lupus anticoagulant (LA) positivity, with high risk of whole gestational APOs. Cluster 3 included patients with isolated aPLs-IgM isotype combined with early miscarriage (60.92%, P = 0.016). Patients in cluster 4 majorly presented aPLs-IgG isotype combined with placenta insufficiency (22.73%). During the follow-up, the live birth rate in cluster 1 and 2 was only 69.20%. Placenta pathology revealed the most severe impairment within cluster 1, whereas clusters 3 and 4 exhibited relatively milder damage. By cluster analysis, we identified four clinical subtypes of aPLs-associated APOs patients. Patients with triple antibodies or high-risk lupus characteristics were prone to occurred gestational hypertension and premature delivery. Isolated LA or aCL/aβ2GPI positivity were found to be more frequently associated with early-stage fetal loss. |
| Author | Huang, Can Li, Mengtao Shi, Xiaohua Xie, Zhijuan Song, Yijun Long, Yin Tian, Xinping Zeng, Xiaofeng Liu, Xinyan Liu, Juntao Cui, Yixin Zhou, Yangzhong Zhao, Jiuliang |
| Author_xml | – sequence: 1 givenname: Yin surname: Long fullname: Long, Yin organization: Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College – sequence: 2 givenname: Can surname: Huang fullname: Huang, Can organization: Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science and Technology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital (PUMCH), Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education – sequence: 3 givenname: Yixin surname: Cui fullname: Cui, Yixin organization: Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College – sequence: 4 givenname: Zhijuan surname: Xie fullname: Xie, Zhijuan organization: Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College – sequence: 5 givenname: Yangzhong surname: Zhou fullname: Zhou, Yangzhong organization: Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science and Technology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital (PUMCH), Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education – sequence: 6 givenname: Xiaohua surname: Shi fullname: Shi, Xiaohua organization: Department of Pathology, Chinese Academy of Medical Sciences & Peking Union Medical College – sequence: 7 givenname: Yijun surname: Song fullname: Song, Yijun organization: Department of Obstetrics, Chinese Academy of Medical Sciences & Peking Union Medical College – sequence: 8 givenname: Xinping surname: Tian fullname: Tian, Xinping organization: National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science and Technology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital (PUMCH), Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education – sequence: 9 givenname: Mengtao surname: Li fullname: Li, Mengtao organization: Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science and Technology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital (PUMCH), Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education – sequence: 10 givenname: Juntao surname: Liu fullname: Liu, Juntao organization: Department of Obstetrics, Chinese Academy of Medical Sciences & Peking Union Medical College – sequence: 11 givenname: Xinyan surname: Liu fullname: Liu, Xinyan email: liuxymeng@163.com organization: Department of Obstetrics, Chinese Academy of Medical Sciences & Peking Union Medical College – sequence: 12 givenname: Xiaofeng surname: Zeng fullname: Zeng, Xiaofeng email: zengxfpumc@163.com organization: Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science and Technology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital (PUMCH), Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education – sequence: 13 givenname: Jiuliang surname: Zhao fullname: Zhao, Jiuliang email: zjlpumc@sina.com organization: Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science and Technology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital (PUMCH), Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37821708$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kTtvHSEQhVHkKH4kfyCFheQmDQkPsbDurKu8JEtp3CMWWBtrL6wZ1vJW_uvh-joPuXDBMDr6zoDOHKODlFNA6COjnxml6gswyoUmrRDKWC_Jwxt0xGTPSC-5PvivP0THALeUMqkFfYcOhdKcKaqP0ONmWqCGgm2y0woRcB5bX-N8k6GdKc7RPwlD9jEAsQDZRVtDU_19KBDwXMJ1ssmtOC_V5W1TbI0hVTjHg4VG5oQtZoKswRbALt_kUjHUxa_v0dvRThA-PN8n6Orb16vND3L56_vPzcUlcULJSpSnvaCDZEJ2kqpOeq8Us06wTgnb9WIYg-5G7pSlnDWCOsmF8N65QTbXCfq0HzuXfLcEqGYbwYVpsinkBQzXquuEFmyHnr1Ab_NSWjqN6ilXLXkmGnX6TC3DNngzl7i1ZTV_km0A3wOuZIASxr8Io2a3PrNfn2nFPK3PPDSTfmFysbYsc6rFxul1q9hbob2TrkP59-1XXL8ByZKv6Q |
| CitedBy_id | crossref_primary_10_1016_j_jri_2024_104316 crossref_primary_10_3390_nu16233975 crossref_primary_10_1016_j_cca_2025_120122 crossref_primary_10_1007_s43032_024_01725_2 crossref_primary_10_47360_1995_4484_2025_12_23 crossref_primary_10_3390_diagnostics14192162 crossref_primary_10_1007_s10067_025_07341_y crossref_primary_10_1016_j_jaut_2024_103237 |
| Cites_doi | 10.1126/science.abc0956 10.1002/art.39453 10.1530/rep.1.01060 10.1016/S0002-9378(96)70610-5 10.1136/lupus-2015-000095 10.1016/S0140-6736(10)60709-X 10.1136/annrheumdis-2017-211641 10.18637/jss.v061.i06 10.1002/art.34473 10.1136/annrheumdis-2016-209770 10.1093/rheumatology/kez419 10.1182/blood-2013-08-522623 10.3389/fimmu.2018.00864 10.3109/14767058.2011.572310 10.1016/j.thromres.2008.03.012 10.7326/M14-2235 10.1111/j.1538-7836.2006.01753.x 10.1093/oxfordjournals.humrep.a136224 10.1186/s13075-022-02814-w 10.1016/j.ajog.2008.03.012 10.1007/s00404-006-0158-7 10.1080/14397595.2017.1386845 10.1093/oxfordjournals.humrep.a019095 10.1093/rheumatology/keaa542 10.1007/s12016-009-8146-x 10.1111/j.1538-7836.2009.03555.x 10.1002/art.34402 10.1016/j.ajog.2015.06.011 10.5858/arpa.2015-0225-CC 10.1093/humrep/17.4.1067 10.1111/j.1538-7836.2010.03747.x 10.1136/lupus-2021-000633 10.1016/j.placenta.2012.03.010 |
| ContentType | Journal Article |
| Copyright | The Author(s), under exclusive licence to Springer Nature Switzerland AG 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG. |
| Copyright_xml | – notice: The Author(s), under exclusive licence to Springer Nature Switzerland AG 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. – notice: 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG. |
| DBID | AAYXX CITATION NPM 7T5 7TK H94 K9. 7X8 |
| DOI | 10.1007/s10238-023-01195-x |
| DatabaseName | CrossRef PubMed Immunology Abstracts Neurosciences Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
| DatabaseTitle | CrossRef PubMed AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts Neurosciences Abstracts MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic AIDS and Cancer Research Abstracts PubMed |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1591-9528 |
| EndPage | 5388 |
| ExternalDocumentID | 37821708 10_1007_s10238_023_01195_x |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: Beijing Municipal Science& Technology Commission grantid: Z201100005520022; 23; 25; 26; 27 – fundername: the Fundamental Research Funds for the Central Universities grantid: 3332022104 – fundername: CAMS Innovation Fund for Medical Sciences grantid: 2021-I2M-1-005 – fundername: Chinese National Key Technology R&D Program grantid: 2021YFC2501300 – fundername: National High Level Hospital Clinical Research Funding grantid: 2022-PUMCH-B-013; A-08 – fundername: Beijing Municipal Science& Technology Commission grantid: 23 – fundername: National High Level Hospital Clinical Research Funding grantid: A-08 – fundername: Beijing Municipal Science& Technology Commission grantid: 27 – fundername: National High Level Hospital Clinical Research Funding grantid: 2022-PUMCH-B-013 – fundername: Beijing Municipal Science& Technology Commission grantid: Z201100005520022 – fundername: Beijing Municipal Science& Technology Commission grantid: 25 – fundername: Beijing Municipal Science& Technology Commission grantid: 26 |
| GroupedDBID | --- -5E -5G -BR -EM -Y2 -~C .86 .GJ .VR 06C 06D 0R~ 0VY 1N0 1SB 203 29B 29~ 2J2 2JN 2JY 2KG 2LR 2P1 2VQ 2~H 30V 36B 3V. 4.4 406 408 409 40D 40E 53G 5VS 67Z 6NX 7X7 875 88E 8AO 8FI 8FJ 8G5 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AAHNG AAIAL AAJKR AAJSJ AAKKN AANXM AANZL AARHV AARTL AATVU AAUYE AAWCG AAYIU AAYQN AAYTO AAYZH ABAKF ABBBX ABBXA ABDZT ABECU ABEEZ ABFTV ABHLI ABHQN ABIPD ABJNI ABJOX ABKCH ABKTR ABLJU ABMNI ABMOR ABMQK ABNWP ABPLI ABQBU ABQSL ABSXP ABTEG ABTKH ABTMW ABULA ABUWG ABWNU ABXPI ACACY ACBXY ACGFS ACHSB ACHXU ACKNC ACMDZ ACMLO ACOKC ACOMO ACPRK ACULB ACZOJ ADBBV ADHHG ADHIR ADIMF ADINQ ADJJI ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADZKW AEBTG AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFEXP AFGXO AFKRA AFLOW AFQWF AFWTZ AFZKB AGAYW AGDGC AGJBK AGMZJ AGQEE AGQMX AGRTI AGWZB AGYKE AHAVH AHBYD AHIZS AHMBA AHSBF AHYZX AIAKS AIIXL AILAN AITGF AJBLW AJRNO AJZVZ AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG AVWKF AXYYD AZFZN AZQEC B-. BA0 BDATZ BENPR BGNMA BPHCQ BVXVI C24 C6C CAG CCPQU COF CS3 CSCUP DDRTE DL5 DNIVK DPUIP DU5 DWQXO EBD EBLON EBS EIOEI EJD EMB EMOBN EN4 ESBYG F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNUQQ GNWQR GQ6 GQ7 GQ8 GUQSH GXS H13 HF~ HG5 HG6 HLICF HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ I09 IHE IJ- IKXTQ IMOTQ ITM IWAJR IXC IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KOV KPH LAS LLZTM M1P M2O M4Y MA- MK0 N2Q N9A NB0 NPVJJ NQJWS NU0 O9- O93 O9I O9J OAM P2P P9S PF0 PQQKQ PROAC PSQYO Q2X QOR QOS R89 R9I RIG ROL RPX RSV S16 S1Z S27 S37 S3B SAP SDH SHX SISQX SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZ9 SZN T13 TSG TSK TSV TT1 TUC U2A U9L UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WJK WK8 YLTOR Z45 Z7U Z87 ZMTXR ZOVNA AASML AAYXX ABDBE ABFSG ACSTC AEZWR AFHIU AHPBZ AHWEU AIXLP AYFIA CITATION NPM 7T5 7TK H94 K9. 7X8 |
| ID | FETCH-LOGICAL-c375t-7d0930b5135650765dd771ac31673a693bfe86f2c7a0215070c5233ddccb5513 |
| IEDL.DBID | U2A |
| ISSN | 1591-9528 1591-8890 |
| IngestDate | Thu Jul 10 17:37:29 EDT 2025 Wed Aug 27 13:33:09 EDT 2025 Wed Feb 19 02:07:58 EST 2025 Thu Apr 24 23:03:44 EDT 2025 Tue Jul 01 02:50:37 EDT 2025 Fri Feb 21 02:40:53 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 8 |
| Keywords | Cluster analysis Adverse pregnancy outcome Antiphospholipid antibody Risk stratification |
| Language | English |
| License | 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c375t-7d0930b5135650765dd771ac31673a693bfe86f2c7a0215070c5233ddccb5513 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| PMID | 37821708 |
| PQID | 2902700713 |
| PQPubID | 43686 |
| PageCount | 12 |
| ParticipantIDs | proquest_miscellaneous_2876638311 proquest_journals_2902700713 pubmed_primary_37821708 crossref_primary_10_1007_s10238_023_01195_x crossref_citationtrail_10_1007_s10238_023_01195_x springer_journals_10_1007_s10238_023_01195_x |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2023-12-01 |
| PublicationDateYYYYMMDD | 2023-12-01 |
| PublicationDate_xml | – month: 12 year: 2023 text: 2023-12-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Cham |
| PublicationPlace_xml | – name: Cham – name: Italy – name: Milano |
| PublicationTitle | Clinical and experimental medicine |
| PublicationTitleAbbrev | Clin Exp Med |
| PublicationTitleAlternate | Clin Exp Med |
| PublicationYear | 2023 |
| Publisher | Springer International Publishing Springer Nature B.V |
| Publisher_xml | – name: Springer International Publishing – name: Springer Nature B.V |
| References | Alijotas-Reig, Esteve-Valverde, Ferrer-Oliveras, Saez-Comet, Lefkou, Mekinian (CR8) 2020; 59 Liu, Zhao, Song, Zhang, Bian, Yang (CR23) 2012; 25 Erton, Sevim, de Jesús, Cervera, Ji, Pengo (CR9) 2022 Blank, Shoenfeld (CR33) 2010; 38 Zammiti, Mtiraoui, Hidar, Fekih, Almawi, Mahjoub (CR29) 2006; 274 Ruffatti, Tonello, Cavazzana, Bagatella, Pengo (CR25) 2009; 123 Skorpen, Lydersen, Gilboe, Skomsvoll, Salvesen, Palm (CR22) 2018; 77 Clowse, Jamison, Myers, James (CR20) 2008; 199 Andreoli, Bertsias, Agmon-Levin, Brown, Cervera, Costedoat-Chalumeau (CR15) 2017; 76 Petri, Orbai, Alarcón, Gordon, Merrill, Fortin (CR16) 2012; 64 Qi, Zhao, Huang, Jiang, Li, Wu (CR13) 2022; 24 Kutteh (CR5) 1996; 174 Müller-Calleja, Hollerbach, Royce, Ritter, Pedrosa, Madhusudhan (CR11) 2021; 371 Kawaguchi, Nunomura, Umehara, Nikaido, Huppertz, Tanaka (CR34) 2012; 33 Mankee, Petri, Magder (CR24) 2015; 2 Fredi, Andreoli, Aggogeri, Bettiga, Lazzaroni, Le Guern (CR10) 2018; 9 Ruiz-Irastorza, Crowther, Branch, Khamashta (CR2) 2010; 376 Balasch, Creus, Fábregues, Reverter, Carmona, Tàssies (CR4) 1996; 11 Lockshin, Kim, Laskin, Guerra, Branch, Merrill (CR6) 2012; 64 Khong, Mooney, Ariel, Balmus, Boyd, Brundler (CR18) 2016; 140 Ogata, Fujieda, Sugawara, Sato, Ohnishi, Kono (CR12) 2021; 60 Pengo, Tripodi, Reber, Rand, Ortel, Galli (CR17) 2009; 7 Charrad, Ghazzali, Boiteau, Niknafs (CR19) 2014; 61 Buyon, Kim, Guerra, Laskin, Petri, Lockshin (CR21) 2015; 163 Zammiti, Mtiraoui, Kallel, Mercier, Almawi, Mahjoub (CR30) 2006; 131 Miyakis, Lockshin, Atsumi, Branch, Brey, Cervera (CR7) 2006; 4 Esplin, Manuck, Varner, Christensen, Biggio, Bukowski (CR14) 2015; 213 Chauleur, Galanaud, Alonso, Cochery-Nouvellon, Balducchi, Marès (CR27) 2010; 8 Ulrich, Gelber, Vukelic, Sacharidou, Herz, Urbanus (CR31) 2016; 68 Branch, Silver, Blackwell, Reading, Scott (CR1) 1992; 80 Sebire, Fox, Backos, Rai, Paterson, Regan (CR32) 2002; 17 Rai, Regan, Clifford, Pickering, Dave, Mackie (CR3) 1995; 10 Bouvier, Cochery-Nouvellon, Lavigne-Lissalde, Mercier, Marchetti, Balducchi (CR28) 2014; 123 Kaneko, Mishima, Goto, Mitsui, Tanigaki, Oku (CR26) 2018; 28 N Müller-Calleja (1195_CR11) 2021; 371 L Andreoli (1195_CR15) 2017; 76 W Qi (1195_CR13) 2022; 24 MEB Clowse (1195_CR20) 2008; 199 J Liu (1195_CR23) 2012; 25 R Kawaguchi (1195_CR34) 2012; 33 MD Lockshin (1195_CR6) 2012; 64 MS Esplin (1195_CR14) 2015; 213 W Zammiti (1195_CR29) 2006; 274 TY Khong (1195_CR18) 2016; 140 M Petri (1195_CR16) 2012; 64 A Mankee (1195_CR24) 2015; 2 M Charrad (1195_CR19) 2014; 61 K Kaneko (1195_CR26) 2018; 28 NJ Sebire (1195_CR32) 2002; 17 S Miyakis (1195_CR7) 2006; 4 V Ulrich (1195_CR31) 2016; 68 DW Branch (1195_CR1) 1992; 80 V Pengo (1195_CR17) 2009; 7 WH Kutteh (1195_CR5) 1996; 174 J Balasch (1195_CR4) 1996; 11 M Blank (1195_CR33) 2010; 38 G Ruiz-Irastorza (1195_CR2) 2010; 376 C Chauleur (1195_CR27) 2010; 8 S Bouvier (1195_CR28) 2014; 123 J Alijotas-Reig (1195_CR8) 2020; 59 ZB Erton (1195_CR9) 2022 A Ruffatti (1195_CR25) 2009; 123 W Zammiti (1195_CR30) 2006; 131 RS Rai (1195_CR3) 1995; 10 M Fredi (1195_CR10) 2018; 9 CG Skorpen (1195_CR22) 2018; 77 Y Ogata (1195_CR12) 2021; 60 JP Buyon (1195_CR21) 2015; 163 |
| References_xml | – volume: 371 start-page: 6534 year: 2021 ident: CR11 article-title: Lipid presentation by the protein C receptor links coagulation with autoimmunity publication-title: Science doi: 10.1126/science.abc0956 – volume: 68 start-page: 730 issue: 3 year: 2016 end-page: 739 ident: CR31 article-title: ApoE receptor 2 mediation of trophoblast dysfunction and pregnancy complications induced by antiphospholipid antibodies in mice publication-title: Arth Rheumatol doi: 10.1002/art.39453 – volume: 131 start-page: 817 issue: 4 year: 2006 end-page: 822 ident: CR30 article-title: A case-control study on the association of idiopathic recurrent pregnancy loss with autoantibodies against beta2-glycoprotein I and annexin V publication-title: Reproduction doi: 10.1530/rep.1.01060 – volume: 174 start-page: 1584 issue: 5 year: 1996 end-page: 1589 ident: CR5 article-title: Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone publication-title: Am J Obstet Gynecol doi: 10.1016/S0002-9378(96)70610-5 – volume: 2 start-page: e000095 issue: 1 year: 2015 ident: CR24 article-title: Lupus anticoagulant, disease activity and low complement in the first trimester are predictive of pregnancy loss publication-title: Lupus Sci Med doi: 10.1136/lupus-2015-000095 – volume: 376 start-page: 1498 issue: 9751 year: 2010 end-page: 1509 ident: CR2 article-title: Antiphospholipid syndrome publication-title: Lancet doi: 10.1016/S0140-6736(10)60709-X – volume: 77 start-page: 264 issue: 2 year: 2018 end-page: 269 ident: CR22 article-title: Influence of disease activity and medications on offspring birth weight, pre-eclampsia and preterm birth in systemic lupus erythematosus: a population-based study publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2017-211641 – volume: 61 start-page: 1 issue: 6 year: 2014 end-page: 36 ident: CR19 article-title: NbClust: an R package for determining the relevant number of clusters in a data set publication-title: J Stat Soft doi: 10.18637/jss.v061.i06 – volume: 64 start-page: 2677 issue: 8 year: 2012 end-page: 2686 ident: CR16 article-title: Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus publication-title: Arthritis Rheum doi: 10.1002/art.34473 – volume: 76 start-page: 476 issue: 3 year: 2017 end-page: 485 ident: CR15 article-title: EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2016-209770 – volume: 59 start-page: 1306 issue: 6 year: 2020 end-page: 1314 ident: CR8 article-title: Comparative study of obstetric antiphospholipid syndrome (OAPS) and non-criteria obstetric APS (NC-OAPS): report of 1640 cases from the EUROAPS registry publication-title: Rheumatology doi: 10.1093/rheumatology/kez419 – volume: 123 start-page: 404 issue: 3 year: 2014 end-page: 413 ident: CR28 article-title: Comparative incidence of pregnancy outcomes in treated obstetric antiphospholipid syndrome: the NOH-APS observational study publication-title: Blood doi: 10.1182/blood-2013-08-522623 – volume: 9 start-page: 864 year: 2018 ident: CR10 article-title: Risk factors for adverse maternal and fetal outcomes in women with confirmed aPL positivity: results from a multicenter study of 283 pregnancies publication-title: Front Immunol doi: 10.3389/fimmu.2018.00864 – volume: 25 start-page: 261 issue: 3 year: 2012 end-page: 266 ident: CR23 article-title: Pregnancy in women with systemic lupus erythematosus: a retrospective study of 111 pregnancies in Chinese women publication-title: J Matern Fetal Neonatal Med Offic J Eur Assoc Perin Med doi: 10.3109/14767058.2011.572310 – volume: 123 start-page: 482 issue: 3 year: 2009 end-page: 487 ident: CR25 article-title: Laboratory classification categories and pregnancy outcome in patients with primary antiphospholipid syndrome prescribed antithrombotic therapy publication-title: Thromb Res doi: 10.1016/j.thromres.2008.03.012 – volume: 163 start-page: 153 issue: 3 year: 2015 end-page: 163 ident: CR21 article-title: Predictors of pregnancy outcomes in patients with lupus: a cohort study publication-title: Ann Intern Med doi: 10.7326/M14-2235 – volume: 4 start-page: 295 issue: 2 year: 2006 end-page: 306 ident: CR7 article-title: International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) publication-title: J Thromb Haemost doi: 10.1111/j.1538-7836.2006.01753.x – volume: 10 start-page: 2001 issue: 8 year: 1995 end-page: 2005 ident: CR3 article-title: Antiphospholipid antibodies and beta 2-glycoprotein-I in 500 women with recurrent miscarriage: results of a comprehensive screening approach publication-title: Hum Reprod doi: 10.1093/oxfordjournals.humrep.a136224 – volume: 24 start-page: 140 issue: 1 year: 2022 ident: CR13 article-title: Clinical characteristics and prognosis of patients with antiphospholipid antibodies based on cluster analysis: an 8-year cohort study publication-title: Arthritis Res Ther doi: 10.1186/s13075-022-02814-w – volume: 199 start-page: 127.e1 issue: 2 year: 2008 end-page: 6 ident: CR20 article-title: A national study of the complications of lupus in pregnancy publication-title: Am J Obstet Gynecol doi: 10.1016/j.ajog.2008.03.012 – volume: 274 start-page: 261 issue: 5 year: 2006 end-page: 265 ident: CR29 article-title: Antibodies to beta2-glycoprotein I and annexin V in women with early and late idiopathic recurrent spontaneous abortions publication-title: Arch Gynecol Obstet doi: 10.1007/s00404-006-0158-7 – volume: 28 start-page: 670 issue: 4 year: 2018 end-page: 675 ident: CR26 article-title: Clinical feature and anti-phospholipid antibody profiles of pregnancy failure in young women with antiphospholipid antibody syndrome treated with conventional therapy publication-title: Mod Rheumatol doi: 10.1080/14397595.2017.1386845 – volume: 80 start-page: 614 issue: 4 year: 1992 end-page: 620 ident: CR1 article-title: Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience publication-title: Obstet Gynecol – volume: 11 start-page: 2310 issue: 10 year: 1996 end-page: 2315 ident: CR4 article-title: Antiphospholipid antibodies and human reproductive failure publication-title: Hum Reprod doi: 10.1093/oxfordjournals.humrep.a019095 – volume: 60 start-page: 1331 issue: 3 year: 2021 end-page: 1337 ident: CR12 article-title: Morbidity and mortality in antiphospholipid syndrome based on cluster analysis: a 10-year longitudinal cohort study publication-title: Rheumatology doi: 10.1093/rheumatology/keaa542 – volume: 38 start-page: 141 issue: 2–3 year: 2010 end-page: 147 ident: CR33 article-title: Antiphospholipid antibody-mediated reproductive failure in antiphospholipid syndrome publication-title: Clin Rev Allergy Immunol doi: 10.1007/s12016-009-8146-x – volume: 7 start-page: 1737 issue: 10 year: 2009 end-page: 1740 ident: CR17 article-title: Update of the guidelines for lupus anticoagulant detection: Subcommittee on lupus anticoagulant/antiphospholipid antibody of the scientific and standardisation committee of the international society on thrombosis and haemostasis publication-title: J Thromb Haemost JTH doi: 10.1111/j.1538-7836.2009.03555.x – volume: 64 start-page: 2311 issue: 7 year: 2012 end-page: 2318 ident: CR6 article-title: Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies publication-title: Arthritis Rheum doi: 10.1002/art.34402 – volume: 213 start-page: 429.e1 issue: 3 year: 2015 end-page: 9 ident: CR14 article-title: Cluster analysis of spontaneous preterm birth phenotypes identifies potential associations among preterm birth mechanisms publication-title: Am J Obstet Gynecol doi: 10.1016/j.ajog.2015.06.011 – volume: 140 start-page: 698 issue: 7 year: 2016 end-page: 713 ident: CR18 article-title: Sampling and definitions of placental lesions: amsterdam placental workshop group consensus statement publication-title: Arch Pathol Lab Med doi: 10.5858/arpa.2015-0225-CC – volume: 17 start-page: 1067 issue: 4 year: 2002 end-page: 1071 ident: CR32 article-title: Defective endovascular trophoblast invasion in primary antiphospholipid antibody syndrome-associated early pregnancy failure publication-title: Human Reprod doi: 10.1093/humrep/17.4.1067 – volume: 8 start-page: 699 issue: 4 year: 2010 end-page: 706 ident: CR27 article-title: Observational study of pregnant women with a previous spontaneous abortion before the 10th gestation week with and without antiphospholipid antibodies publication-title: J Thromb Haemost doi: 10.1111/j.1538-7836.2010.03747.x – year: 2022 ident: CR9 article-title: Pregnancy outcomes in antiphospholipid antibody positive patients: prospective results from the antiphospholipid syndrome alliance for clinical trials and international networking (APS ACTION) clinical database and repository ('Registry') publication-title: Lupus Sci Med doi: 10.1136/lupus-2021-000633 – volume: 33 start-page: 540 issue: 7 year: 2012 end-page: 547 ident: CR34 article-title: Multiple injections of anti-mouse β2glycoprotein 1 antibody induce FcRγ-dependent fetal growth restriction (FGR) in mice publication-title: Placenta doi: 10.1016/j.placenta.2012.03.010 – volume: 33 start-page: 540 issue: 7 year: 2012 ident: 1195_CR34 publication-title: Placenta doi: 10.1016/j.placenta.2012.03.010 – volume: 28 start-page: 670 issue: 4 year: 2018 ident: 1195_CR26 publication-title: Mod Rheumatol doi: 10.1080/14397595.2017.1386845 – volume: 274 start-page: 261 issue: 5 year: 2006 ident: 1195_CR29 publication-title: Arch Gynecol Obstet doi: 10.1007/s00404-006-0158-7 – volume: 38 start-page: 141 issue: 2–3 year: 2010 ident: 1195_CR33 publication-title: Clin Rev Allergy Immunol doi: 10.1007/s12016-009-8146-x – volume: 61 start-page: 1 issue: 6 year: 2014 ident: 1195_CR19 publication-title: J Stat Soft doi: 10.18637/jss.v061.i06 – volume: 64 start-page: 2677 issue: 8 year: 2012 ident: 1195_CR16 publication-title: Arthritis Rheum doi: 10.1002/art.34473 – volume: 80 start-page: 614 issue: 4 year: 1992 ident: 1195_CR1 publication-title: Obstet Gynecol – volume: 10 start-page: 2001 issue: 8 year: 1995 ident: 1195_CR3 publication-title: Hum Reprod doi: 10.1093/oxfordjournals.humrep.a136224 – volume: 7 start-page: 1737 issue: 10 year: 2009 ident: 1195_CR17 publication-title: J Thromb Haemost JTH doi: 10.1111/j.1538-7836.2009.03555.x – year: 2022 ident: 1195_CR9 publication-title: Lupus Sci Med doi: 10.1136/lupus-2021-000633 – volume: 68 start-page: 730 issue: 3 year: 2016 ident: 1195_CR31 publication-title: Arth Rheumatol doi: 10.1002/art.39453 – volume: 140 start-page: 698 issue: 7 year: 2016 ident: 1195_CR18 publication-title: Arch Pathol Lab Med doi: 10.5858/arpa.2015-0225-CC – volume: 4 start-page: 295 issue: 2 year: 2006 ident: 1195_CR7 publication-title: J Thromb Haemost doi: 10.1111/j.1538-7836.2006.01753.x – volume: 24 start-page: 140 issue: 1 year: 2022 ident: 1195_CR13 publication-title: Arthritis Res Ther doi: 10.1186/s13075-022-02814-w – volume: 213 start-page: 429.e1 issue: 3 year: 2015 ident: 1195_CR14 publication-title: Am J Obstet Gynecol doi: 10.1016/j.ajog.2015.06.011 – volume: 9 start-page: 864 year: 2018 ident: 1195_CR10 publication-title: Front Immunol doi: 10.3389/fimmu.2018.00864 – volume: 76 start-page: 476 issue: 3 year: 2017 ident: 1195_CR15 publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2016-209770 – volume: 371 start-page: 6534 year: 2021 ident: 1195_CR11 publication-title: Science doi: 10.1126/science.abc0956 – volume: 64 start-page: 2311 issue: 7 year: 2012 ident: 1195_CR6 publication-title: Arthritis Rheum doi: 10.1002/art.34402 – volume: 8 start-page: 699 issue: 4 year: 2010 ident: 1195_CR27 publication-title: J Thromb Haemost doi: 10.1111/j.1538-7836.2010.03747.x – volume: 25 start-page: 261 issue: 3 year: 2012 ident: 1195_CR23 publication-title: J Matern Fetal Neonatal Med Offic J Eur Assoc Perin Med doi: 10.3109/14767058.2011.572310 – volume: 59 start-page: 1306 issue: 6 year: 2020 ident: 1195_CR8 publication-title: Rheumatology doi: 10.1093/rheumatology/kez419 – volume: 60 start-page: 1331 issue: 3 year: 2021 ident: 1195_CR12 publication-title: Rheumatology doi: 10.1093/rheumatology/keaa542 – volume: 11 start-page: 2310 issue: 10 year: 1996 ident: 1195_CR4 publication-title: Hum Reprod doi: 10.1093/oxfordjournals.humrep.a019095 – volume: 174 start-page: 1584 issue: 5 year: 1996 ident: 1195_CR5 publication-title: Am J Obstet Gynecol doi: 10.1016/S0002-9378(96)70610-5 – volume: 123 start-page: 404 issue: 3 year: 2014 ident: 1195_CR28 publication-title: Blood doi: 10.1182/blood-2013-08-522623 – volume: 131 start-page: 817 issue: 4 year: 2006 ident: 1195_CR30 publication-title: Reproduction doi: 10.1530/rep.1.01060 – volume: 163 start-page: 153 issue: 3 year: 2015 ident: 1195_CR21 publication-title: Ann Intern Med doi: 10.7326/M14-2235 – volume: 123 start-page: 482 issue: 3 year: 2009 ident: 1195_CR25 publication-title: Thromb Res doi: 10.1016/j.thromres.2008.03.012 – volume: 17 start-page: 1067 issue: 4 year: 2002 ident: 1195_CR32 publication-title: Human Reprod doi: 10.1093/humrep/17.4.1067 – volume: 376 start-page: 1498 issue: 9751 year: 2010 ident: 1195_CR2 publication-title: Lancet doi: 10.1016/S0140-6736(10)60709-X – volume: 2 start-page: e000095 issue: 1 year: 2015 ident: 1195_CR24 publication-title: Lupus Sci Med doi: 10.1136/lupus-2015-000095 – volume: 199 start-page: 127.e1 issue: 2 year: 2008 ident: 1195_CR20 publication-title: Am J Obstet Gynecol doi: 10.1016/j.ajog.2008.03.012 – volume: 77 start-page: 264 issue: 2 year: 2018 ident: 1195_CR22 publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2017-211641 |
| SSID | ssj0015830 |
| Score | 2.3684666 |
| Snippet | Antiphospholipid antibodies (aPLs) are the leading causes of adverse pregnancy outcomes (APOs). We conducted cluster analysis to identify distinct phenotypes... |
| SourceID | proquest pubmed crossref springer |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 5377 |
| SubjectTerms | Antibodies Antiphospholipid antibodies Cluster analysis Fetuses Hematology Hypertension Immunoglobulin G Immunoglobulin M Internal Medicine Medicine Medicine & Public Health Oncology Patients Phenotypes Placenta Pregnancy |
| Title | Cluster analysis of antiphospholipid antibodies-associated adverse pregnancy outcome patients: based on a 13-years cohort study |
| URI | https://link.springer.com/article/10.1007/s10238-023-01195-x https://www.ncbi.nlm.nih.gov/pubmed/37821708 https://www.proquest.com/docview/2902700713 https://www.proquest.com/docview/2876638311 |
| Volume | 23 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1LS8QwEB5EQbyIb-uLCN400DabPrwt4gNFTwp6KnlVF5Z22XbBPfnXnbTpqvgADw0lTdOSSWa-MJNvAI5w2kRMpZxylUqKCDykUiY-5cZwE_kq4cp6dG_voquH3vUjf3SHwqou2r1zSTaa-tNhNzQvFAva8JRRRI4LHPfuNpDrIezPfAc8Yb47HvPze19N0Ddc-c0n2piaixVYdhiR9FuhrsKcKdZg8dZ5wdfh7Ww4sfwGRDhGEVLmeF8PRi9lhddwMBropkKWNkiQCicDg7U2AXNlyGhsni3XxpSUkxoHAGtahtXqlFjLpklZEEECRqe4FipiE-mOa9Kw0W7A_cX5_dkVdYkUqGIxr2ms_ZT5kgcM4RsKh2sdx4FQ9hQ8E1HKZG6SKA9VLCwEQC2gcH_KtFZK2gQwmzBflIXZBpKHvoi0DLSIe72UGSFSpnASYBc8Uir3IOiGNlOOZNzmuhhmH_TIVhwZFlkjjuzVg-PZO6OWYuPP1nudxDK33KosTH3rQMcNtweHs8e4UKz3QxSmnGAb1PuobFgQeLDVSnr2OYY4KYj9xIOTTvQfnf_-Lzv_a74LSzZZfRsMswfz9Xhi9hHS1PIAFvqXTzfnB81Mfgf7mvE3 |
| linkProvider | Springer Nature |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwED-NTgJe0PjOGGAkeAJLSVznA2kP1WDqunUvFGlvlr8yKlVJ1aTa-sQfs39059TpQAMkHvYQK3Icx_Ld5e50vt8BvEe2SZjOOeU6VxQt8JgqlYWUW8ttEuqMaxfRHZ8mw-_90Rk_24KrLhemPe3ehSTbP_UvyW6oXig2tMUpo5f-KOWxXV2go1bvH31Bqn6I48Ovk4Mh9bUEqGYpb2hq0HUPFY8YWjC4Pm5MmkZSu0RwJpOcqcJmSRHrVDotiIKg0UVjxmitXA0UnPYebGc8yXgPtgeD0bfRJljBMxb6fJw_L_R3nXfLkL0VhG112-EOPPJGKRmsuegxbNnyCdwf-7D7U_h5MFs6QAUiPYQJqQq8b6bzH1WN12w6n5q2Q1XuVCKVnugWe13F59qS-cKeO3CPFamWDe449qwhXevPxKlSQ6qSSBIxusL9romr3LtoSAt_-wwmd7Hbz6FXVqV9CaSIQ5kYFRmZ9vs5s1LmTCPX4RQ80boIIOq2VmiPau6Ka8zEDR6zI4fARrTkEJcBfNy8M19jevxz9F5HMeHluxZxHrqIPXr4AbzbPEbJdOEWWdpqiWNQ0eDfjUVRAC_WlN58jqFhFqVhFsCnjvQ3k_99Lbv_N_wtPBhOxifi5Oj0-BU8jB1Ltidx9qDXLJb2NdpTjXrj-ZmAuGMJugawHitf |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1LT9wwEB5RKqFeqr6blhZXak-tRRKv80DqAQErKAX1ABI3y6-0K62SaJNV2VN_Uv8i48RZiqBIHDjEihzHsTwzmRmN5xuAj8g2CdM5p1zniqIFHlOlspBya7lNQp1x7SK6R8fJ_uno2xk_W4G_Qy5Md9p9CEn2OQ0OpalsN2tTbP6T-IaqhmJDO8wyeu6PVR7axW902pqvB7tI4U9xPN472dmnvq4A1SzlLU0NuvGh4hFDawbXyo1J00hqlxTOZJIzVdgsKWKdSqcRUSg0umvMGK2Vq4eC0z6AhyOXfIwCdBpvL8MWPGOhz8y5eZlXtd81k_ZaOLbTcuMn8Nibp2S756ensGLLZ7B25APwz-HPznTuoBWI9GAmpCrwvp3Uv6oGr-mknpiuQ1XufCKVnvwWe13t58aSemZ_OpiPBanmLe499vTgrs0WcUrVkKokkkSMLnC3G-Jq-M5a0gHhvoCT-9jrl7BaVqV9DaSIQ5kYFRmZjkY5s1LmTCP_4RQ80boIIBq2VmiPb-7KbEzFJTKzI4fARnTkEOcBfF6-U_foHreOXh8oJrykNyLOQxe7R18_gA_LxyijLvAiS1vNcQyqHPzPsSgK4FVP6eXnGJpoURpmAXwZSH85-f_X8uZuwzdg7cfuWHw_OD58C49ix5HdkZx1WG1nc_sODatWve-YmYC4Z-G5AOodLkY |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Cluster+analysis+of+antiphospholipid+antibodies-associated+adverse+pregnancy+outcome+patients%3A+based+on+a+13-years+cohort+study&rft.jtitle=Clinical+and+experimental+medicine&rft.au=Long%2C+Yin&rft.au=Huang%2C+Can&rft.au=Cui%2C+Yixin&rft.au=Xie%2C+Zhijuan&rft.date=2023-12-01&rft.issn=1591-9528&rft.eissn=1591-9528&rft.volume=23&rft.issue=8&rft.spage=5377&rft.epage=5388&rft_id=info:doi/10.1007%2Fs10238-023-01195-x&rft.externalDBID=n%2Fa&rft.externalDocID=10_1007_s10238_023_01195_x |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1591-9528&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1591-9528&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1591-9528&client=summon |